Exogenous adiponectin attenuates lipid accumulation and is associated with enhanced TG and VLDL secretion in primary chicken hepatocytes Authors: Dan Wang, Qingmei Hu, Kelin Li, Qing Jia, Hai Lin, Jingpeng Zhao, Hongchao Jiao, Xiaojuan Wang Published: 2026 ABSTRACT Adiponectin (ADPN) is an adipocyte-derived peptide that exerts a pivotal regulatory role in lipid metabolism in mammals. However, its functional role in avian lipid metabolism needs to be further explored, particularly in the liver, the central organ governing metabolic homeostasis in poultry. In this study, the effects of exogenous recombinant adiponectin on lipid metabolism processes were examined in primary chicken hepatocytes. Regardless of palmitic acid pretreatment, adiponectin significantly attenuated intracellular lipid accumulation. Mechanistically, adiponectin was accompanied by increased adiponectin receptor 2 (ADPNR2) mRNA expression and stimulated the efflux of triglycerides (TG) and very low-density lipoproteins (VLDL) from hepatocytes. These effects were accompanied by short-term activation of the AMP-activated protein kinase (AMPK) signaling pathway. Meanwhile, adiponectin enhanced the cellular uptake of glucose and fatty acids and upregulated the expression of genes related to fatty acid synthesis. It also suppressed the expression of genes involved in fatty acid oxidation, suggesting a cell-intrinsic negative feedback mechanism. In conclusion, the results indicate that enhanced lipid efflux may be an important mechanism contributing to the adiponectin-mediated reduction of hepatic lipid accumulation. These findings provide further evidence for the involvement of adiponectin in the regulation of avian hepatic lipid metabolism and suggest that adiponectin and its receptor pathways may represent potential targets for future studies aimed at improving liver health and productivity in poultry. Introduction Lipid metabolism plays a crucial role in poultry production, as it not only regulates energy supply and storage to meet the energy demands for egg production and yolk formation but also exerts a key impact on the growth performance and meat quality of broilers. Previous studies have shown that 70% of fatty acid synthesis in chickens occurs in hepatocytes, 5% in adipose tissue, and the remaining 25% is derived from the diet (Wang et al., 2023). Hepatic lipid metabolic disorders can induce a series of health problems. In laying hens, they may lead to Fatty Liver Hemorrhagic Syndrome (FLHS), which is typically associated with a significant decline in egg production (Liu et al., 2024) and sudden death in high-yielding individuals (Shini et al., 2019). In broilers, increased fat deposition reduces feed conversion efficiency and systemic disease resistance, impairs carcass quality, and thereby decreases meat yield (Cai et al., 2021). All these issues result in substantial economic losses in the poultry industry. Therefore, maintaining normal hepatic lipid metabolism is of paramount importance for sustainable poultry production. Adiponectin is an endogenous peptide specifically secreted by adipocytes (Yanai et al., 2019) and possesses diverse biological activities, including the regulation of glucose and lipid metabolism, suppression of inflammatory factor secretion, and improvement of endothelial cell function (Choi et al., 2020). It is also closely associated with obesity, insulin resistance, type 2 diabetes mellitus, and gut microbiota composition (Zhao et al., 2020b; Khoramipour et al., 2021). Clinical studies have shown that patients with non-alcoholic fatty liver disease (NAFLD) have significantly lower levels of adiponectin in both liver tissue and serum compared to healthy individuals, suggesting that adiponectin may be involved in the pathogenesis of NAFLD (Mavilia et al., 2021). Moreover, the clinical improvement of adiponectin levels has been shown to positively regulate lipid metabolism (Abhijit et al., 2018). Preclinical studies further confirmed that adiponectin can reduce hepatic triglycerides (TG) in mice (Li et al., 2020). According to current research, adiponectin improves hepatic lipid metabolism through multiple mechanisms. A typical pathway involves the binding of adiponectin to its receptors, Adiponectin Receptor 1 (ADPNR1) or Adiponectin Receptor 2 (ADPNR2), which in turn activate downstream signaling pathways (Xing et al., 2024). Specifically, ADPNR1 and ADPNR2 mediate AMP-activated protein kinase (AMPK) / Mitogen-Activated Protein Kinase (MAPK) and peroxisome proliferator-activated receptor (PPAR) signaling respectively, thereby exerting effects of promoting fatty acid oxidation and alleviating fat accumulation (Kadowaki et al., 2006; Li et al., 2011; Fang et al., 2018). Ramachandran et al. (2007) first cloned the full-length cDNA encoding chicken ADPNR1 and ADPNR2, revealing 76%–83% sequence homology between these avian receptors and their mammalian homologs. Both receptors are detectable in liver tissue; hepatic ADPNR2 mRNA exhibits far higher abundance, with expression levels surpassed only by adipose and skeletal muscle. By contrast, ADPNR1 shows comparatively weak hepatic transcription (Ramachandran et al., 2007; Cai et al., 2021). In addition, ADPNR2 mRNA expression has been reported to be positively correlated with intramuscular fat content in chickens (Zhang et al., 2017), further implying its potential specificity in regulating hepatic lipid metabolism. To date, research on the regulatory role of adiponectin in animal lipid metabolism has been extensively conducted in mammals (Choi et al., 2018; Tang et al., 2020; Hassan et al., 2021). Parallel research exploring adiponectin signaling in poultry lipid metabolism is gradually expanding (Cai et al., 2021; Hu et al., 2022). Notably, lipid metabolism in poultry differs from that in mammals, with the liver serving as the primary organ responsible for lipid metabolic processes in poultry (Griffin et al., 1992; Wang et al., 2020b). This physiological divergence highlights the value of further investigating adiponectin’s hepatic regulatory actions and the associated molecular pathways in chickens. Based on the aforementioned evidence, we propose the research hypothesis that exogenous adiponectin might mitigate hepatic lipid accumulation in chickens by binding to its liver-predominant receptor ADPNR2. Accordingly, the present study aims to verify this hypothesis using primary chicken hepatocytes as an in vitro model, explore the potential mechanisms by which adiponectin regulates avian hepatic lipid metabolism, and ultimately provide theoretical support and potential solutions for the prevention and control of fatty liver disease in the poultry industry. Materials and methods Preparation and identification of recombinant adiponectin protein Recombinant chicken adiponectin protein was prepared and identified by Jinan Boshang Biotechnology Co., Ltd. (Jinan, China). The protein was expressed using an Escherichia coli (E. coli) expression system, with the coding sequence derived from the chicken adiponectin gene (GenBank Accession No.: NM_206991). Animals treatments Sixty 28-day-old Arbor Acres male broilers with comparable body weights were selected, and randomly allocated into two treatment groups. The broilers were fed a high-energy diet (HED) and a low-energy diet (LED), respectively, as detailed in Table 1, with one chicken per replicate. After one week of feeding, each chicken was weighted, subsequently euthanized, and samples were collected. All experimental procedures were approved by the Animal Care and Use Committee of Shandong Agriculture University (Approval No. SDAUA-2013-019) and conducted in strict compliance with the Guidelines for Experimental Animals established by the Ministry of Science and Technology (Beijing, China).Table 1The composition of the experimental diet.Table 1 dummy alt textIngredient, %LEDHEDCorn48.0348.33Soya-bean oil-13.11Soybean meal27.0933.65Iodized salt0.260.26Limestone1.911.75Calcium hydrophosphate1.451.68Choline chloride0.260.26Lysine (65%)0.330.40Methionine (99%)0.260.32Wheat bran20.18-Mineral mix10.200.20Vitamin mix20.050.03Nutrient levelMetabolizable energy, MJ/Kg10.9115.11Crude protein, %20.0020.00Calcium, %1.001.00Available Phosphorus, %0.450.45Sodium chloride, %0.250.25Lysine, %0.971.08Methionine, %0.550.57Methionine+cysteine, %0.790.81Threonine, %0.550.59Tryptophan, %0.180.181: Mineral premix provides the following per kg of diet: Fe (as ferrous sulfate), 55 mg; Zn (as zinc sulfate), 88 mg; Mn (as manganese sulfate), 88 mg; Cu (as copper sulfate) 5.5 mg; I (as potassium iodide), 1.7 mg; Se (as sodium selenite), 0.3 mg.2: Vitamin premix provides the following per kg of diet: VA, 8800 IU; VD3, 3300 IU; VE, 16.5 IU; VK, 2.2 mg; VB1, 1.7 mg; VB2, 5.5 mg; VB3, 6.6 mg; VB5, 28 mg; VB6, 3.3 mg; VB7, 0.1 mg; VB9, 0.6 mg; VB12, 0.05 mg. Table 1The composition of the experimental diet.Table 1 dummy alt textIngredient, %LEDHEDCorn48.0348.33Soya-bean oil-13.11Soybean meal27.0933.65Iodized salt0.260.26Limestone1.911.75Calcium hydrophosphate1.451.68Choline chloride0.260.26Lysine (65%)0.330.40Methionine (99%)0.260.32Wheat bran20.18-Mineral mix10.200.20Vitamin mix20.050.03Nutrient levelMetabolizable energy, MJ/Kg10.9115.11Crude protein, %20.0020.00Calcium, %1.001.00Available Phosphorus, %0.450.45Sodium chloride, %0.250.25Lysine, %0.971.08Methionine, %0.550.57Methionine+cysteine, %0.790.81Threonine, %0.550.59Tryptophan, %0.180.181: Mineral premix provides the following per kg of diet: Fe (as ferrous sulfate), 55 mg; Zn (as zinc sulfate), 88 mg; Mn (as manganese sulfate), 88 mg; Cu (as copper sulfate) 5.5 mg; I (as potassium iodide), 1.7 mg; Se (as sodium selenite), 0.3 mg.2: Vitamin premix provides the following per kg of diet: VA, 8800 IU; VD3, 3300 IU; VE, 16.5 IU; VK, 2.2 mg; VB1, 1.7 mg; VB2, 5.5 mg; VB3, 6.6 mg; VB5, 28 mg; VB6, 3.3 mg; VB7, 0.1 mg; VB9, 0.6 mg; VB12, 0.05 mg. The composition of the experimental diet. 1: Mineral premix provides the following per kg of diet: Fe (as ferrous sulfate), 55 mg; Zn (as zinc sulfate), 88 mg; Mn (as manganese sulfate), 88 mg; Cu (as copper sulfate) 5.5 mg; I (as potassium iodide), 1.7 mg; Se (as sodium selenite), 0.3 mg. 2: Vitamin premix provides the following per kg of diet: VA, 8800 IU; VD3, 3300 IU; VE, 16.5 IU; VK, 2.2 mg; VB1, 1.7 mg; VB2, 5.5 mg; VB3, 6.6 mg; VB5, 28 mg; VB6, 3.3 mg; VB7, 0.1 mg; VB9, 0.6 mg; VB12, 0.05 mg. Cell culture and treatments Cell culture Specific pathogen-free (SPF) fertilized eggs were obtained from a commercial source (Jinan SAIS Poultry Co., Ltd., China). The eggs were from White Leghorn chickens (Gallus gallus domesticus), the most commonly used breed for SPF egg production. The eggs were incubated at 37°C with a relative humidity of 60% to 70% until the required embryonic stage. Embryos at 15 days of age were regarded as the optimal stage for hepatocyte isolation, because they could provide sufficient cell yield with high viability and retention of key hepatic functions (Kennedy et al., 1996; Head and Kennedy, 2007). Hepatocytes were isolated and cultured according to the methods by Hahn (1997). The isolated hepatocytes were cultured in William's E medium (Gibco, Thermo Fisher Scientific, Shanghai, China) supplemented with 12% foetal bovine serum and 1% penicillin/streptomycin (Solarbio, Beijing, China) in a humidified 5% CO2 atmosphere at 37°C until the cells reached approximately 80% confluence. Palmitic acid (PA) preparation PA was prepared according to the method described by Hu et al. (2022). Specifically, PA was dissolved in a mixture of 50% ethanol and 10 mol/L NaOH, which was heated to 60°C to obtain a clear solution. This solution was then immediately mixed with fatty acid free-BSA. Adiponectin treatment Unless otherwise specified, hepatocytes were divided into different groups as follows: (1) control group (no adiponectin and no PA treatment); (2) PA group (pretreated with 300 μM PA in serum-free medium for 24 h without adiponectin treatment); (3) adiponectin (ADPN) group (treated with 5 μg/mL recombinant adiponectin for 24 h without PA pretreatment); (4) PA + ADPN group (pretreated with 300 μM PA in serum-free medium for 24 h, followed by 5 μg/mL recombinant adiponectin treatment for 24 h). After treatment, the cells were rinsed with 1×PBS (Solarbio, Beijing, China), collected and subjected to further analysis. Additionally, for western blot analysis, cells were collected at 30 min, 1 h, 6 h, 12 h and 24 h after the initiation of recombinant adiponectin treatment, respectively. The concentrations of ADPN and PA were selected based on our previous studies (Cai et al., 2021; Hu et al., 2022). Detection of intracellular components Adiponectin, TG and Hepatic Lipase (HL) were quantified using commercial assay kits (Nanjing Jiancheng Bioengineering Institute, China). The concentration of Very Low-Density Lipoprotein (VLDL) was determined following the method described by Griffin and Whitehead (1982). Briefly, 0.2 mL of the culture medium was mixed thoroughly with 4 mL of heparin-Mg reagent, which was prepared by dissolving 30.495 g of MgCl2, 8.9998 g of NaCl, 0.25 g of heparin in 1 L of 0.05 M Tris-HCl buffer (pH 7.4). After incubation at room temperature for 30 min (with a maximum allowable duration of 45 min), the absorbance of the mixture was measured at a wavelength of 540 nm. Fatty Acid Synthase (FAS) activity was assayed according to the protocol established by Halestrap and Denton (1973). First, the target cells were lysed in pre-chilled homogenization buffer (0.25 mol/L sucrose, 1 mmol/L DTT, 1 mmol/L EDTA, pH 7.4). The lysate was then centrifuged at 100,000 × g for 1 h, and the resulting supernatant collected as the crude enzyme solution. A 100 μL aliquot of the enzyme solution was added to 1 mL of pre-warmed (37°C) 0.1 mol/L phosphate buffer containing 0.1 mmol/L NADPH and 25 μmol/L acetyl CoA (pH 6.5). The reaction was initiated by the rapid addition of 50 μL of 1.38 mmol/L malonyl CoA, and the absorbance change was monitored at 340 nm over a 1-min period. One unit of FAS activity was defined as the amount of enzyme required to catalyze the conversion of 1 nmol of NADPH (substrate) to NADP+ (product) per milligram of tissue protein within 1 min under the specified reaction conditions. Malate Enzyme (ME) activity was determined using the method of Khundmiri et al. (2004). A 50 μL aliquot of the same crude enzyme solution prepared for FAS assay was added to 1 mL of pre-warmed (37°C) 50 mmol/L HEPES buffer, which contained 1 mmol/L NADP+ and 10 mmol/L MgSO4 (pH 7.5). The reaction was started by adding 50 μL of 44 mmol/L l-malate rapidly, and the absorbance variation was measured at 340 nm for 1 min. One unit of ME activity was defined as the quantity of enzyme that catalyzes the production of 1 nmol of NADPH from NADP+ per milligram of tissue protein within 1 min in the above reaction system. Oil Red O staining and bodipy staining The Oil Red O staining method was modified based on the protocols described by Zhang et al. (2019) and Zhao et al. (2020a). Briefly, cells were washed twice with 1×PBS and then fixed with 4% formaldehyde for 30 min. Subsequent to fixation, cells were stained with 0.6% oil red O solution for 30 min, followed by counterstaining of cell nuclei with haematoxylin for 5 min. After thorough washing, the stained cultures were imaged using an inverted microscope (Olympus, Japan). For bodipy staining, cells were first immobilized with 4% paraformaldehyde at room temperature for 30 min. Thereafter, cells were stained with Bodipy staining solution (1 μg/mL) for 30 min in the dark, followed by incubation with an appropriate volume of DAPI staining solution (1 μg/mL) for 5 min. Observation and imaging were performed using an ultra-high resolution laser confocal microscope (Zeiss, Germany). Glucose and fatty acid uptake assays Glucose uptake was quantified using Glucose Uptake Assay Kit (Cayman Chemical, United States), based on the cellular uptake of a fluorescently labeled deoxyglucose analog, 2-NBDG (2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]−2-deoxy-d-glucose), following the manufacturer's standard protocols. After the experimental treatment, the culture medium in each well was aspirated and replaced with fresh medium either lacking 2-NBDG (negative control) or supplemented with 2-NBDG at a final concentration of 200 µg/mL. The cells were then incubated at 37°C under 5% CO2 for 40 min. Subsequently, 10000 single-cell suspensions were prepared and subjected to fluorescence detection and quantitative analysis using a BD LSRFortessa flow cytometer (BD Biosciences, San Jose, CA, United States). Fatty acid uptake was evaluated using the QBT Fatty Acid Uptake Assay Kit (Molecular Devices, United States), which relies on the cellular internalization of fluorescently labeled fatty acids probes. After experimental treatment, the culture medium was discarded, and cells were incubated with fresh medium containing either no fluorescent fatty acids (negative control) or fluorescent fatty acids at a final concentration of 300 µg/mL. The incubation was carried out at 37°C with 5% CO2 for 10 min. A total of 10000 single cells were collected, and the fluorescence intensity was measured and quantified using the BD LSRFortessa flow cytometer (BD Biosciences, San Jose, CA, United States). Real-time PCR analysis Total RNA extraction and qRT-PCR were conducted following the methods described previously (Liu et al., 2019a; Wang et al., 2020a). Cellular total RNA was isolated using TransZol Up reagent (New Cell & Molecular Biotech Co.,Ltd, Jiangsu, China). RNA concentration was quantified via spectrophotometry (Eppendorf, Germany), while RNA integrity and purity were validated by calculating the absorbance ratio at 260 and 280 nm (A260/280 ≈ 1.8-2.1) as well as by electrophoresis. Subsequently, 1 μg of total RNA was reverse-transcribed into first-strand cDNA synthesis using the Transcriptor First Strand cDNA Synthesis Kit (Beijing ComWin Biotech Co.,Ltd., Beijing, China). Real-time PCR amplification was carried out on an ABI QuantStudio 5 PCR machine (Applied Biosystems; Thermo, USA) with MagicSYBR Mixture (Beijing ComWin Biotech Co.,Ltd., Beijing, China). The specific primer sequences employed in this assay are listed in Table 2. The PCR products were verified by DNA sequencing and electrophoresis. Standard curves were constructed using serial dilutions of cDNA derived from the experimental samples. Relative mRNA expression levels of target genes were calculated using the 2−ΔΔCT method (Chen et al., 2018; Tang et al., 2019) with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) serving as the reference gene for normalization (Liu et al., 2016; Wang et al., 2018).Table 2Gene-specific primers used for the analysis of chicken gene expression.Table 2 dummy alt textGeneSequences (5′→3′)Accession NO.Product size (bp)ADPNF: ACCCAGACACAGATGACCGTTNM_206991238R: GAGCAAGAGCAGAGGTAGGAGTADPNR1F: GGAGAAGGTTGTGTTTGGGATGTNM_001031027218R: TGGAGAGGTAGATGAGTCTTGGCADPNR2F: ACACACAGAGACTGGCAACATCNM_001007854144R: CCCAAGAAGAACAATCCAACAACCFASF: CTATCGACACAGCCTGCTCCTJ03860107R: CAGAATGTTGACCCCTCCTACCPPARγF: CCAGCGACATCGACCAGTTAF163811145R: GGTGATTTGTCTGTCGTCTTTCCSREBP1F: GCCCTCTGTGCCTTTGTCTTCNM_204126.2130R: ACTCAGCCATGATGCTTCTTCCPGC1αF: GACTCAGGTGTCAATGGAAGTGXM_040647116.2272R: ATCAGAACAAGCCCTGTGGTL-CPT1F: GGGACCTGAAACCAGAGAACGAY675193215R: ACAGAGGAGGGCATAGAGGATGGAPDHF: ACATGGCATCCAAGGAGTGAGNM_204305.1244R: GGGGAGACAGAAGGGAACAGA Table 2Gene-specific primers used for the analysis of chicken gene expression.Table 2 dummy alt textGeneSequences (5′→3′)Accession NO.Product size (bp)ADPNF: ACCCAGACACAGATGACCGTTNM_206991238R: GAGCAAGAGCAGAGGTAGGAGTADPNR1F: GGAGAAGGTTGTGTTTGGGATGTNM_001031027218R: TGGAGAGGTAGATGAGTCTTGGCADPNR2F: ACACACAGAGACTGGCAACATCNM_001007854144R: CCCAAGAAGAACAATCCAACAACCFASF: CTATCGACACAGCCTGCTCCTJ03860107R: CAGAATGTTGACCCCTCCTACCPPARγF: CCAGCGACATCGACCAGTTAF163811145R: GGTGATTTGTCTGTCGTCTTTCCSREBP1F: GCCCTCTGTGCCTTTGTCTTCNM_204126.2130R: ACTCAGCCATGATGCTTCTTCCPGC1αF: GACTCAGGTGTCAATGGAAGTGXM_040647116.2272R: ATCAGAACAAGCCCTGTGGTL-CPT1F: GGGACCTGAAACCAGAGAACGAY675193215R: ACAGAGGAGGGCATAGAGGATGGAPDHF: ACATGGCATCCAAGGAGTGAGNM_204305.1244R: GGGGAGACAGAAGGGAACAGA Gene-specific primers used for the analysis of chicken gene expression. Western blot Cells were homogenized in lysis buffer (Beyotime, Jiangsu, China). The homogenate was centrifuged at 12000 × g at 4°C for 10 min and the supernatant was collected. Protein quantification was performed using the BCA protein Assay Kit (Beyotime, Jiangsu, China) following the manufacturer's protocol. Aliquots of 30 μg protein were subjected to electrophoresis on a 7.5% SDS-polyacrylamide gel, and the separated proteins were transferred onto polyvinylidene fluoride membranes using western transfer buffer. The membrane was blocked prior to incubation with the following primary antibodies with a dilution of 1:1000: anti-phospho-AMPKα (Thr 172) (Rabbit, #2531), anti-AMPKα (Rabbit, #2532), anti-phospho-acetyl CoA carboxylase (ACC) (Ser79) (Rabbit, #3661), anti-ACC (Rabbit, #3662), and anti-carnitine palmitoyl transferase 1 (CPT1) (Rabbit, #12252) purchased from CST (Boston, MA, United States); antibody peroxisome proliferator-activated receptor γ coactivator 1 (PGC1) α (#ab54481) purchased from Abcam (Cambridge, Britain); antibody PGC1β customized by Wuhan Jinkairui Bioengineering Co., LTD. Protein detection was performed using horseradish peroxidase-linked anti-rabbit secondary antibodies (A0208, 1:1000, Beyotime, Shanghai, China) with enhanced chemiluminescence plus western blot detection reagents. All these antibodies have been previously validated for use with chicken samples (Neumeier et al., 2006; Zhang et al., 2019). The films were scanned, and the intensities of specific bands were quantified using BioSpectrum 810 with VisionWorks LS 7.1 software (UVP LLC) (Uerlings et al., 2018; Li et al., 2024). Band intensities were normalized to the levels of β-actin (Beyotime, Shanghai, China) or tubulin (Beyotime, Shanghai, China) in the same sample. Protein molecular weight markers were used to verify the target proteins. Statistical analysis Statistical analysis of the data was performed using SAS statistical software (SAS version 8e, SAS Institute, Cary, NC, USA). For comparisons among multiple groups, one-way analysis of variance (ANOVA) followed by Duncan’s Multiple Range test was used. For comparisons between two groups, an unpaired Student's t-test was performed. P < 0.05 was considered statistically significant, and P < 0.10 was defined as a tendency approaching statistical significance. Results Dietary energy levels may affect serum adiponectin concentration As presented in Table 3, chickens fed the HED exhibited a significantly higher average daily weight gain compared with those receiving the LED after a 1-week feeding period (P < 0.0001). No significant differences were observed in liver weight, as well as hepatic TG and VLDL contents (P > 0.01). However, serum adiponectin concentration showed a tendency toward significant elevation in the HED group (P = 0.0606). Additionally, although the hepatic mRNA expression levels of ADPN, ADPNR1, and ADPNR2 did not reach statistical significance (P > 0.01), notable numerical fluctuations were detected across the dietary treatments.Table 3Characteristic features of HED and LED fed chicken.Table 3 dummy alt textLEDHEDP valueBody weight gain (g/d)33.78 ± 2.84b61.05 ± 4.83a< 0.0001Liver weight (g)46.37 ± 2.4348.83 ± 2.710.5134Liver proportion (g/100 g Body weight)3.09 ± 0.253.04 ± 0.150.8731Serum VLDL content (O.D.)0.016 ± 0.0010.022 ± 0.0040.2075Serum TG content (mmol/L)0.39 ± 0.040.40 ± 0.030.8505Serum ADPN content (μg/mL)4.98 ± 0.426.16 ± 0.370.0606Hepatic ADPN mRNA level (Fold of HED)1.33 ± 0.101.00 ± 0.120.6951Hepatic ADPNR1 mRNA level (Fold of HED)1.14 ± 0.311.00 ± 0.130.4218Hepatic ADPNR2 mRNA level (Fold of HED)1.42 ± 0.271.00 ± 0.130.5909Note: The test data are expressed as Mean ± standard deviation (Mean ± SD), with n = 30 for body weight gain, n = 6 for other indicators. Numbers with different superscript letters in the same lines indicate a significant difference (P < 0.05). Abbreviations: HED = high-energy diet group; LED = low-energy diet group; TG = triglycerides; VLDL = very low-density lipoproteins; ADPN = adiponectin; ADPNR = adiponectin receptor. Table 3Characteristic features of HED and LED fed chicken.Table 3 dummy alt textLEDHEDP valueBody weight gain (g/d)33.78 ± 2.84b61.05 ± 4.83a< 0.0001Liver weight (g)46.37 ± 2.4348.83 ± 2.710.5134Liver proportion (g/100 g Body weight)3.09 ± 0.253.04 ± 0.150.8731Serum VLDL content (O.D.)0.016 ± 0.0010.022 ± 0.0040.2075Serum TG content (mmol/L)0.39 ± 0.040.40 ± 0.030.8505Serum ADPN content (μg/mL)4.98 ± 0.426.16 ± 0.370.0606Hepatic ADPN mRNA level (Fold of HED)1.33 ± 0.101.00 ± 0.120.6951Hepatic ADPNR1 mRNA level (Fold of HED)1.14 ± 0.311.00 ± 0.130.4218Hepatic ADPNR2 mRNA level (Fold of HED)1.42 ± 0.271.00 ± 0.130.5909Note: The test data are expressed as Mean ± standard deviation (Mean ± SD), with n = 30 for body weight gain, n = 6 for other indicators. Numbers with different superscript letters in the same lines indicate a significant difference (P < 0.05). Abbreviations: HED = high-energy diet group; LED = low-energy diet group; TG = triglycerides; VLDL = very low-density lipoproteins; ADPN = adiponectin; ADPNR = adiponectin receptor. Characteristic features of HED and LED fed chicken. Note: The test data are expressed as Mean ± standard deviation (Mean ± SD), with n = 30 for body weight gain, n = 6 for other indicators. Numbers with different superscript letters in the same lines indicate a significant difference (P < 0.05). Abbreviations: HED = high-energy diet group; LED = low-energy diet group; TG = triglycerides; VLDL = very low-density lipoproteins; ADPN = adiponectin; ADPNR = adiponectin receptor. The regulatory role of adiponectin on lipid accumulation and efflux in hepatocytes To elucidate the role of adiponectin in hepatic lipid metabolism, we treated primary hepatocytes with recombinant adiponectin, with or without prior PA pretreatment. The results showed that 24 h recombinant adiponectin treatment significantly enhanced cell viability (P < 0.05) (Supplementary Fig. 1A). Compared with the PA-only group, TG content was dose-dependently reduced in adiponectin-treated cells (P < 0.05) (Fig. 1A, Supplementary Fig. 1B). Oil Red O staining assays revealed a marked increase in intracellular lipid droplet abundance following PA exposure, whereas adiponectin intervention led to a significant reduction in lipid droplet accumulation (Fig. 1B, Supplementary Fig. 1C). Consistent findings were obtained via BODIPY staining (Fig. 1C). Subsequently, we quantified the concentrations of VLDL and TG in the hepatocyte culture supernatant. Relative to the untreated Con group, adiponectin supplementation significantly elevated VLDL levels in the supernatant (P < 0.001) and exhibited a tendency to increase supernatant TG content (P = 0.08) (Fig. 1D-E). Moreover, in PA-pretreated hepatocytes, the addition of recombinant adiponectin also significantly upregulated both VLDL and TG concentrations in the culture supernatant (P < 0.05) (Fig. 1D-E). In addition, PA treatment alone increased not only intracellular TG but also the secretion of TG and VLDL into the culture medium (Fig. 1A, D, E). Collectively, these results indicate that adiponectin facilitates the efflux of intracellular TG and VLDL to the extracellular environment, thereby alleviating hepatic lipid accumulation.Fig. 1Effect of recombinant adiponectin on intracellular and extracellular lipid contents in primary chicken hepatocytes. (A) Intracellular TG content. (B) Oil red O staining results (10 × 40). The red ones are lipid droplets and the blue ones are cell nuclei. (C) Bodipy staining results (20 μm). The green ones are lipid droplets and the blue ones are cell nuclei. (D) TG content in the cell medium. (E) VLDL content in the cell medium. P < 0.1 tendency, * P < 0.05, ** P < 0.01, *** P < 0.001. Data are presented as mean ± SD (n = 6).Fig 1 dummy alt text Effect of recombinant adiponectin on intracellular and extracellular lipid contents in primary chicken hepatocytes. (A) Intracellular TG content. (B) Oil red O staining results (10 × 40). The red ones are lipid droplets and the blue ones are cell nuclei. (C) Bodipy staining results (20 μm). The green ones are lipid droplets and the blue ones are cell nuclei. (D) TG content in the cell medium. (E) VLDL content in the cell medium. P < 0.1 tendency, * P < 0.05, ** P < 0.01, *** P < 0.001. Data are presented as mean ± SD (n = 6). Effects of adiponectin on fatty acid and glucose uptake in hepatocytes Flow cytometric assays revealed that recombinant adiponectin markedly promoted both glucose and fatty acid uptake in hepatocytes, irrespective of whether the cells were pretreated with PA or not (P < 0.05) (Fig. 2A-D). Notably, PA pretreatment alone significantly suppressed glucose uptake in hepatocytes (P < 0.05), whereas it exerted no significant effect on fatty acid uptake by these cells (P > 0.1) (Fig. 2A-D).Fig. 2Effects of recombinant adiponectin on fatty acid and glucose uptake in primary chicken hepatocytes. (A-B) Fatty acid uptake. (C-D) Glucose uptake. * P < 0.05, ** P < 0.01, *** P < 0.001. Data are presented as mean ± SD (n = 6).Fig 2 dummy alt text Effects of recombinant adiponectin on fatty acid and glucose uptake in primary chicken hepatocytes. (A-B) Fatty acid uptake. (C-D) Glucose uptake. * P < 0.05, ** P < 0.01, *** P < 0.001. Data are presented as mean ± SD (n = 6). Effects of adiponectin on the expression of lipid metabolism-related genes and enzyme activities We first detected the mRNA expression levels of ADPNR in hepatocytes following recombinant adiponectin treatment. The results indicated that under PA pretreatment, adiponectin enhanced the expression of ADPNR2 but not ADPNR1, and this regulatory effect exhibited a concentration-dependent pattern (Fig. 3A, Supplementary Fig. 1D-E).Fig. 3Effects of recombinant adiponectin on lipid metabolism-related gene expression and enzyme activities in primary chicken hepatocytes. (A-F) The mRNA expression of (A) ADPNR2, (B) FAS, (C) PPARγ, (D) SREBP1, (E) l-CPT1 and (F) PGC1α in primary chicken hepatocytes. (G-I) The enzymatic activities of (G) FAS, (H) ME and (I) HL in primary chicken hepatocytes. P < 0.1 tendency, * P < 0.05, ** P < 0.01, *** P < 0.001. Data are expressed as Mean ± SD (n = 6).Fig 3 dummy alt text Effects of recombinant adiponectin on lipid metabolism-related gene expression and enzyme activities in primary chicken hepatocytes. (A-F) The mRNA expression of (A) ADPNR2, (B) FAS, (C) PPARγ, (D) SREBP1, (E) l-CPT1 and (F) PGC1α in primary chicken hepatocytes. (G-I) The enzymatic activities of (G) FAS, (H) ME and (I) HL in primary chicken hepatocytes. P < 0.1 tendency, * P < 0.05, ** P < 0.01, *** P < 0.001. Data are expressed as Mean ± SD (n = 6). Subsequently, we analyzed the expression profiles of lipid metabolism-associated genes. In the absence of PA pretreatment, adiponectin significantly upregulated the mRNA expression of PPARγ (P < 0.01) and showed a tendency to increase SREBP1 expression (P = 0.09) (Fig. 3C-D). In contrast, in PA-pretreated hepatocytes, adiponectin treatment led to a significant upregulation of both PPARγ and SREBP1 (P < 0.01) (Fig. 3C-D). With respect to lipid oxidation-related genes, adiponectin administration—either alone or subsequent to PA pretreatment—significantly downregulated the expression of l-CPT1 (P < 0.05), whereas it had no significant effect on PGC1α expression (P > 0.1) (Fig. 3E–F). Additionally, compared with the non-PA control group, a 24-hour PA treatment alone significantly upregulated the mRNA levels of PPARγ, CPT1, and PGC1α, while concurrently downregulating SREBP1 expression (P < 0.05) (Fig. 3C–F). Given that neither PA nor adiponectin treatment induced significant changes in FAS mRNA expression (P > 0.1) (Fig. 3B), we further assessed FAS enzymatic activity. Notably, adiponectin treatment alone significantly reduced FAS activity (P < 0.05), whereas it exerted a moderate increasing effect on this enzyme activity following PA pretreatment (P = 0.07) (Fig. 3G). Furthermore, adiponectin treatment with PA pretreatment slightly elevated ME activity (P = 0.08). Adiponectin exerted no discernible effect on HL activity (P > 0.1), while PA treatment alone resulted in a significant increase in HL activity (P < 0.01) (Fig. 3H-I). Effects of adiponectin on the AMPK signaling pathway and associated protein expression in hepatocytes To elucidate the potential signaling pathways involved in adiponectin action, we conducted a time-course analysis of AMPK-related protein expression in hepatocytes treated with recombinant adiponectin. At 30 min post-adiponectin treatment, no significant alterations were detected in the phosphorylation levels of AMPK or ACC (P > 0.1) (Fig. 4A-C). Adiponectin treatment alone exerted a slight increasing effect on CPT1 protein expression (P = 0.08) (Fig. 4A, D). By contrast, compared with PA treatment alone, adiponectin intervention following PA pretreatment tended to downregulate PGC1α expression (P = 0.06) (Fig. 5A-B).Fig. 4Temporal effects of recombinant adiponectin on the AMPK signaling pathway and related protein expression in primary chicken hepatocytes. (A) Representative western blot bands of AMPK, ACC and CPT1 proteins at 30 min time point. (B-D) Relative protein expression levels of (B) AMPK, (C) ACC and (D) CPT1 at 30 min. (E) Representative western blot bands of AMPK, ACC, and CPT1 proteins at 1 h time point. (F-H) Relative protein expression levels of (F) AMPK, (G) ACC and (H) CPT1 at 1 h. (I) Representative western blot bands of AMPK, ACC, and CPT1 proteins at 6 h time point. (J-L) Relative protein expression levels of (J) AMPK, (K) ACC and (L) CPT1 at 6 h. (M) Representative western blot bands of AMPK, ACC, and CPT1 proteins at 12 h time point. (N-P) Relative protein expression levels of (N) AMPK, (O) ACC and (P) CPT1 at 12 h. (Q) Representative western blot bands of AMPK, ACC, and CPT1 proteins at 24 h time point. (R-T) Relative protein expression levels of (R) AMPK, (S) ACC and (T) CPT1 at 24 h. P < 0.1 tendency, * P < 0.05, ** P < 0.01, *** P < 0.001. Data are expressed as Mean ± SD (n = 6).Fig 4 dummy alt textFig. 5Temporal effects of recombinant adiponectin on PGC family protein expression in primary chicken hepatocytes. (A) Representative western blot bands of PGC1α and PGC1β proteins at 30 min time point. (B-C) Relative protein expression levels of (B) PGC1α and (C) PGC1β at 30 min. (D) Representative western blot bands of PGC1α and PGC1β proteins at 1 h time point. (E-F) Relative protein expression levels of (E) PGC1α and (F) PGC1β at 1 h. (G) Representative western blot bands of PGC1α and PGC1β proteins at 6 h time point. (H-I) Relative protein expression level of (H) PGC1α and (I) PGC1β at 6 h. (J) Representative western blot bands of PGC1α and PGC1β proteins at 12 h time point. (K-L) Relative protein expression levels of (K) PGC1α and (L) PGC1β at 12 h. (M) Representative western blot bands of PGC1α and PGC1β proteins at 24 h time point. (N—O) Relative protein expression levels of (N) PGC1α and (O) PGC1β at 24 h. P < 0.1 tendency, * P < 0.05, ** P < 0.01. Data are expressed as Mean ± SD (n = 6).Fig 5 dummy alt text Temporal effects of recombinant adiponectin on the AMPK signaling pathway and related protein expression in primary chicken hepatocytes. (A) Representative western blot bands of AMPK, ACC and CPT1 proteins at 30 min time point. (B-D) Relative protein expression levels of (B) AMPK, (C) ACC and (D) CPT1 at 30 min. (E) Representative western blot bands of AMPK, ACC, and CPT1 proteins at 1 h time point. (F-H) Relative protein expression levels of (F) AMPK, (G) ACC and (H) CPT1 at 1 h. (I) Representative western blot bands of AMPK, ACC, and CPT1 proteins at 6 h time point. (J-L) Relative protein expression levels of (J) AMPK, (K) ACC and (L) CPT1 at 6 h. (M) Representative western blot bands of AMPK, ACC, and CPT1 proteins at 12 h time point. (N-P) Relative protein expression levels of (N) AMPK, (O) ACC and (P) CPT1 at 12 h. (Q) Representative western blot bands of AMPK, ACC, and CPT1 proteins at 24 h time point. (R-T) Relative protein expression levels of (R) AMPK, (S) ACC and (T) CPT1 at 24 h. P < 0.1 tendency, * P < 0.05, ** P < 0.01, *** P < 0.001. Data are expressed as Mean ± SD (n = 6). Temporal effects of recombinant adiponectin on PGC family protein expression in primary chicken hepatocytes. (A) Representative western blot bands of PGC1α and PGC1β proteins at 30 min time point. (B-C) Relative protein expression levels of (B) PGC1α and (C) PGC1β at 30 min. (D) Representative western blot bands of PGC1α and PGC1β proteins at 1 h time point. (E-F) Relative protein expression levels of (E) PGC1α and (F) PGC1β at 1 h. (G) Representative western blot bands of PGC1α and PGC1β proteins at 6 h time point. (H-I) Relative protein expression level of (H) PGC1α and (I) PGC1β at 6 h. (J) Representative western blot bands of PGC1α and PGC1β proteins at 12 h time point. (K-L) Relative protein expression levels of (K) PGC1α and (L) PGC1β at 12 h. (M) Representative western blot bands of PGC1α and PGC1β proteins at 24 h time point. (N—O) Relative protein expression levels of (N) PGC1α and (O) PGC1β at 24 h. P < 0.1 tendency, * P < 0.05, ** P < 0.01. Data are expressed as Mean ± SD (n = 6). At the 1 h time point, adiponectin treatment alone significantly activated ACC phosphorylation (P < 0.01). Meanwhile, in PA-pretreated hepatocytes, adiponectin supplementation exhibited a tendency to enhance AMPK phosphorylation (P = 0.07) and significantly promoted ACC phosphorylation (P = 0.05) (Fig. 4E-G). No significant changes were observed in expression of CPT1, PGC1α, or PGC1β (P > 0.1) (Fig. 4E, H; Fig. 5D-F). At 6 h, adiponectin treatment alone slightly suppressed AMPK phosphorylation (P = 0.06) (Fig. 4I-J) but markedly upregulated CPT1 expression (P < 0.05) (Fig. 4I, L). Its effects on ACC activation and PGC1α/PGC1β expression were negligible (P > 0.1) (Fig. 4K; Fig. 5G-I). At 12 h, adiponectin modestly increased total AMPK protein levels (P = 0.07) without exerting a significant impact on the phosphorylation status of AMPK or ACC (P > 0.1) (Fig. 4M-O). Similarly, the expression levels of CPT1, PGC1α and PGC1β remained unaffected (P > 0.1) (Fig. 5J-L). At 24 h, adiponectin treatment significantly elevated both phosphorylated ACC (P < 0.01) and total ACC protein levels (P < 0.05), whereas the p-ACC/ACC ratio remained unchanged (Fig. 4Q, S). Additionally, adiponectin markedly upregulated PGC1β expression (P < 0.01) (Fig. 5M, O). Moreover, compared with the PA-only group, adiponectin treatment following PA pretreatment significantly reduced AMPK phosphorylation as well as the expression of CPT1, PGC1α, and PGC1β (P < 0.05) (Fig. 4Q, R, T; Fig. 5M-O). Discussion The involvement of adiponectin in hepatic lipid metabolism of chickens Unlike mammals, poultry are characterized by higher circulating glucose levels and lower insulin concentrations (Dupont et al., 2004; Braun and Sweazea, 2008), implying inherent differences in glucose and lipid metabolic pathways between avian and mammalian species. In the present study, broiler chickens were assigned to either a HED or a LED treatment group. Although a one-week feeding trial failed to induce significant alterations in serum TG and VLDL concentrations or liver weight, serum adiponectin levels were found to be numerically higher in the HED group relative to the LED group. These results suggest that adiponectin may play a role in modulating energy homeostasis and lipid metabolism in broilers. The liver serves as the central hub for lipid synthesis, degradation, and transport, and its regulatory mechanisms in lipid metabolism have long been a research priority. Extensive studies in rodents and humans have confirmed that adiponectin is a key regulator of hepatic lipid metabolism (Berg et al., 2002; Titchenell et al., 2017; Moyce et al., 2022). In the current study, we detected the hepatic mRNA expression of ADPN, ADPNR1, and ADPNR2; notably, the hepatic expression of ADPNR2 in the LED group was numerically 42% higher than that in the HED group, despite the absence of a statistically significant difference. This observation raises the possibility that, similar to its role in mammals, adiponectin may also be involved in the regulation of hepatic lipid metabolism in poultry. The results in vivo provided the basis for subsequent in vitro investigations in primary chicken hepatocytes. To further validate this hypothesis, primary chicken hepatocytes were treated with recombinant adiponectin. Primary hepatocytes are widely regarded as one of the most physiologically relevant in vitro liver models, as they retain many liver-specific metabolic functions and key characteristics of native hepatic tissue (Godoy et al., 2013; Zeilinger et al., 2016). The results showed that adiponectin markedly reduced intracellular lipid content. This finding aligns with previous observations in rabbits, cattle, mice, and humans (Yamauchi et al., 2001; Schindler et al., 2017; Chen et al., 2013; Christou et al., 2013; Chaffin et al., 2022). These findings suggest that targeting adiponectin signaling to prevent hepatic lipid metabolic disorders and improve liver health seems to be a possible approach. ADPNR2 may act as a major hepatic receptor mediating adiponectin signaling in chickens Adiponectin exerts its pleiotropic biological effects—encompassing the regulation of systemic energy homeostasis, insulin resistance, inflammatory responses, and lipid metabolism—via binding to its cognate receptors (Yu et al., 2011; Peng et al., 2018). Two major adiponectin receptors have been identified to date, namely ADPNR1 and ADPNR2. In mammals, ADPNR1 is widely recognized as a high-affinity receptor for globular adiponectin in skeletal muscle and a low-affinity receptor for full-length adiponectin, whereas ADPNR2 functions as an intermediate-affinity receptor for both globular and high-molecular-weight adiponectin isoforms in the liver (Yamauchi et al., 2003, 2014). In the present study, we demonstrated that under PA pretreatment, recombinant adiponectin dose-dependently increased ADPNR2 mRNA expression in primary chicken hepatocytes, whereas it exerted minimal effects on ADPNR1. These findings imply that adiponectin may primarily mediate its biological functions through ADPNR2 in chicken hepatocytes. By contrast, in bovine hepatocytes, adiponectin transduces signals through both ADPNR1 and ADPNR2, with a preferential binding affinity for ADPNR2 (Chen et al., 2013). Moreover, our previous study has reported that adiponectin is capable of activating both ADPNR1 and ADPNR2 signaling pathways in chicken myoblasts (Hu et al., 2022), indicating a tissue-specific pattern of adiponectin receptor utilization in avian species. Facilitating TG and VLDL efflux represents an important mechanism through which adiponectin alleviates intracellular lipid accumulation in chicken hepatocytes Lipid metabolism constitutes a highly intricate process encompassing lipid synthesis, degradation, and oxidative utilization. In poultry, the liver is a main site for lipid metabolism (Yang et al., 2025), where fatty acids are either oxidized, synthesized into TG, or secreted as VLDL (Ress et al., 2016). Therefore, we comprehensively evaluated the effects of adiponectin on fatty acid uptake, synthesis, and oxidation, as well as TG export (Pramfalk et al., 2016), to elucidate the dominant pathways responsible for its lipid-lowering effects. Initially, we measured TG and VLDL levels in the culture medium as indicators of hepatic lipid export capacity. The results demonstrated that adiponectin treatment significantly elevated TG and VLDL concentrations in the supernatant, suggesting that adiponectin promotes the efflux of TG and VLDL from hepatocytes. This finding confirms that enhancing lipid export is an important mechanism by which adiponectin attenuates intracellular lipid accumulation. Subsequently, we observed that adiponectin enhances the uptake of both glucose and fatty acids in chicken hepatocytes. Accumulating evidence in mammals has demonstrated that adiponectin acts on the liver and other target organs to enhance glucose uptake and fatty acid oxidation, thereby exerting a protective effect against hepatic steatosis (You et al., 2018). In agreement with these observations, we found that adiponectin-mediated fatty acid uptake was also elevated. These metabolic changes are likely driven by AMPK activation, which facilitates the translocation of GLUT transporters and upregulates fatty acid transporters such as CD36 (Ceddia et al., 2005; Samovski et al., 2015). Indeed, our results confirmed that AMPK was activated as early as 1 h following adiponectin treatment. Liu et al. (2012) reported that the expression of genes encoding key rate-limiting enzymes in hepatic lipid metabolism was markedly altered in adiponectin-knockout mice, indicating that adiponectin could modulate these processes at the transcriptional level. We therefore analyzed key lipogenic regulators in this context. FAS and ME—rate-limiting enzymes in fatty acid synthesis—play indispensable roles in lipid metabolism in animals (Gonzalez-Bohorquez et al., 2022). Our data showed that FAS mRNA levels remained unaltered; however, adiponectin treatment following PA pretreatment tended to enhance the enzymatic activities of both FAS and ME. Additionally, PPARγ is a nuclear receptor transcription factor that acts as a critical regulatory hub in the hepatic lipid metabolism (Grygiel-Górniak et al., 2014). Upon heterodimerization with the retinoic acid X receptor, PPARγ binds to peroxisome proliferator-responsive elements and modulates the expression of genes involved in adipogenesis, fatty acid uptake, TG storage, and insulin sensitivity (Yu et al., 2023). SREBP1c directly regulates the transcription of genes associated with glycolysis and lipogenesis, including those encoding stearoyl-CoA desaturase and FAS (Horton et al., 2002). Chen et al. (2012) reported that adiponectin dose-dependently downregulated the expression of SREBP1c and its downstream target genes (ACCα, SCD-1, and FAS) in bovine hepatocytes. In contrast, the present study demonstrated that adiponectin upregulated the mRNA expression of both PPARγ and SREBP1 regardless of PA pretreatment, indicating that adiponectin promotes de novo lipid synthesis in primary chicken hepatocytes. To further elucidate the role of adiponectin in lipid oxidation, we examined the expression of CPT1—a core gene governing fatty acid β-oxidation (Choi et al., 2024). Our results revealed a temporal dichotomy: adiponectin treatment markedly elevated CPT1 protein abundance at 6 h, yet decreased the mRNA and protein levels of CPT1 at 24 h. This suggests that adiponectin promotes β-oxidation acutely but inhibits it during prolonged exposure. Additionally, the transcriptional coactivator PGC-1α and PGC-1β are explored (Song et al., 2010). PGC-1α is typically activated by the AMPK-SIRT1-PGC1α signaling pathway to drive β-oxidation (Huang et al., 2014). PGC-1β acts as a ligand to bind with estrogen receptor-related receptors ligand 1 to promote the expression of β-oxidation-related enzymes, such as medium-chain acyl CoA dehydrogenase (Kamei et al., 2003). Our data demonstrated that, under PA pretreatment, adiponectin significantly inhibited PGC-1α protein levels at 24 h despite unchanged mRNA expression. Similarly, PGC-1β protein expression was suppressed by adiponectin following PA pretreatment; conversely, adiponectin alone markedly increased PGC-1β expression at 24 h. Given that PGC-1β can also coactivate the SREBP transcription factor family to promote lipid synthesis (Lin et al., 2005), we hypothesized that the activation of PGC-1β was involved in the lipid synthesis-related pathways in the absence of PA pretreatment. Collectively, these findings indicate that adiponectin under PA pretreatment interferes with PGC-mediated regulation of lipid oxidation, ultimately inhibiting β-oxidation in chicken hepatocytes. Notably, PGC-1α was not activated despite AMPK activation at 1 h, implying that PGC-1α regulation in chickens may involve signaling pathways distinct from the canonical AMPK axis. In mice, adiponectin has been reported to improve insulin sensitivity, reduce circulating insulin, suppress lipogenesis, and facilitate fatty acid oxidation, thereby mitigating hepatic lipid accumulation (Miller et al., 2011). However, our findings contradict these conventional observations. In chicken hepatocytes, we demonstrate that adiponectin enhances fatty acid and glucose uptake as well as lipogenesis while concurrently suppressing lipid oxidation, although short-term adiponectin treatment transiently increases CPT1 expression through AMPK activation. We propose that the robust export of intracellular TG reduces cellular lipid loads, thereby alleviating the demand for β-oxidation as the primary clearance pathway (van Zwol et al., 2024). Furthermore, these findings align with previous studies indicating that fatty acid uptake and TG synthesis are subject to negative feedback regulation (Manco et al., 2000; Liu et al., 2019b). Therefore, we propose that in chicken hepatocytes, these long-term effects of adiponectin represent a feedback regulatory mechanism that prevents excessive depletion of intracellular free fatty acids following sustained TG and VLDL export. Adiponectin may modulate hepatic lipid metabolism via the AMPK signaling pathway in the short term AMPK is a serine/threonine protein kinase that functions as a master cellular energy sensor in mammals, orchestrating the regulation of glucose homeostasis and lipid metabolism (Hardie, 2011; Jeon, 2016). Mechanistically, AMPK phosphorylates and inhibits ACC activity, thereby reducing intracellular malonyl-CoA levels. This process relieves the inhibitory effect of malonyl-CoA on CPT1, ultimately facilitating fatty acid translocation into mitochondria to augment β-oxidation (Zammit and Arduini, 2008; Hardie et al., 2012). Accumulating evidence has demonstrated that adiponectin enhances hepatic lipid oxidation and suppresses TG synthesis by activating the AMPK signaling pathway in mammalian models (Tilg and Moschen, 2010; Combs and Marliss, 2014). Notably, the AMPK signaling cascade in chickens shares a high degree of conservation with that in mammals (Proszkowiec-Weglarz et al., 2006), and prior studies have confirmed that adiponectin regulates fatty acid-induced mitochondrial biogenesis via the AMPK-ACC pathway in avian species (Gan et al., 2015). To elucidate the temporal dynamics of AMPK pathway activation by adiponectin in chicken hepatocytes, we treated primary hepatocytes with recombinant adiponectin and examined the protein expression and phosphorylation levels of AMPK, ACC, and CPT1 at time points of 30 min, 1 h, 6 h, 12 h and 24 h respectively. The results showed that AMPK was activated by adiponectin at 1 h post-PA pretreatment, whereas its phosphorylation was markedly suppressed at 24 h time point. This finding aligns with observations in bovine hepatocytes, where AMPKα phosphorylation was enhanced at 4 h post-adiponectin treatment but gradually diminished over time (Chen et al., 2013), indicating that adiponectin-mediated AMPK activation may be a transient response. Consistently, ACC phosphorylation was activated in parallel with AMPK at 1 h after PA pretreatment, whereas CPT1 expression was significantly upregulated only after 6 h and reduced simultaneously when AMPK was inhibited at 24 h of adiponectin exposure. This time-lagged response suggests that the sequential activation of AMPK-ACC—CPT1 does not occur synchronously in chicken hepatocytes. These results are consistent with the findings of Yoon et al. (2006), who reported that adiponectin sequentially activates AMPK and its downstream signaling molecules to promote fatty acid oxidation in skeletal muscle cells. Collectively, these data indicate that adiponectin may modulate lipid metabolism in chicken hepatocytes via the AMPK-ACC—CPT1 signaling pathway in a temporally dependent manner. Interestingly, it is well established that in mammals, adiponectin binding to ADPNR1 activates the AMPK pathway to regulate glucose and lipid metabolism, thereby improving insulin sensitivity and inhibiting de novo lipogenesis (Yamauchi et al., 2002; Li et al., 2011). In contrast, ADPNR2 signaling enhances the PPARα cascade to promote fatty acid oxidation and alleviate lipid accumulation (Kadowaki et al., 2006). In the present study, adiponectin did not activate ADPNR1 mRNA expression but effectively activated the AMPK-ACC—CPT1 pathway at the protein level. This discrepancy suggests that the molecular mechanism underlying adiponectin-mediated lipid metabolism regulation in the avian liver may diverge from that characterized in other species. In conclusion, the present study demonstrates that adiponectin participates in the regulation of hepatic lipid metabolism in chickens and alleviates intracellular lipid accumulation in primary chicken hepatocytes. The proposed regulatory mechanism is illustrated in Fig. 6, the observed effects may be associated with increased ADPNR2 expression following adiponectin treatment. Enhanced TG and VLDL efflux may represent an important mechanism contributing to the reduction of intracellular lipid accumulation. In addition, adiponectin may modulate hepatic lipid metabolism via the AMPK signaling pathway in the short term, potentially promoting fatty acid and glucose uptake as well as fatty acid oxidation; Furthermore, the changes observed following prolonged adiponectin treatment may suggest the existence of a feedback regulatory response associated with sustained lipid efflux, which could contribute to increased fatty acid and glucose uptake, enhanced lipogenesis, and reduced fatty acid oxidation. However, the causal relationships underlying these processes require further experimental validation. Taken together, this study provides novel insights into the mechanisms underlying adiponectin-regulated hepatic lipid metabolism in chickens and contributes to a better understanding of avian lipid metabolism. These findings provide a theoretical foundation for future studies on the prevention and mitigation of lipid metabolic disorders in poultry. Furthermore, modulation of adiponectin or its receptor pathways may have potential for improving liver health and productivity in poultry; however, the further in vivo studies are required to confirm their physiological relevance and practical applicability.Fig. 6Proposed mechanism underlying adiponectin-mediated attenuation of hepatic lipid deposition in chickens. Adiponectin treatment was accompanied by increased ADPNR2 mRNA expression and enhanced TG and VLDL secretion from hepatocytes. Enhanced lipid efflux may represent an important mechanism contributing to the reduction of intracellular lipid accumulation. In addition, (A) in the short term, adiponectin may modulate hepatic lipid metabolism through the AMPK-ACC—CPT1 signaling pathway, potentially promoting fatty acid β-oxidation as well as fatty acid and glucose uptake (Ceddia et al., 2005; Samovski et al., 2015); (B) In the long term, the observed increases in fatty acid and glucose uptake, enhanced lipogenesis, and reduced fatty acid oxidation may suggest the existence of a feedback regulatory response associated with sustained lipid efflux. However, the causal relationships among the above processes remain to be experimentally validated. Collectively, these findings suggest that enhanced lipid efflux may be an important mechanism by which adiponectin alleviates lipid accumulation in chicken hepatocytes.Fig 6 dummy alt text Proposed mechanism underlying adiponectin-mediated attenuation of hepatic lipid deposition in chickens. Adiponectin treatment was accompanied by increased ADPNR2 mRNA expression and enhanced TG and VLDL secretion from hepatocytes. Enhanced lipid efflux may represent an important mechanism contributing to the reduction of intracellular lipid accumulation. In addition, (A) in the short term, adiponectin may modulate hepatic lipid metabolism through the AMPK-ACC—CPT1 signaling pathway, potentially promoting fatty acid β-oxidation as well as fatty acid and glucose uptake (Ceddia et al., 2005; Samovski et al., 2015); (B) In the long term, the observed increases in fatty acid and glucose uptake, enhanced lipogenesis, and reduced fatty acid oxidation may suggest the existence of a feedback regulatory response associated with sustained lipid efflux. However, the causal relationships among the above processes remain to be experimentally validated. Collectively, these findings suggest that enhanced lipid efflux may be an important mechanism by which adiponectin alleviates lipid accumulation in chicken hepatocytes. Funding This work was supported by the 10.13039/501100001809National Natural Science Foundation of China (32372937; 32172787), the 10.13039/100014103Key Research and Development Program of Shandong province (2025CXPT157), the Special Fund of the Taishan Scholars Program (tsqn202507140), and 10.13039/501100009997Modern Agro-industry Technology Research System (CARS-40-K09). CRediT authorship contribution statement Dan Wang: Writing – original draft, Visualization, Validation. Qingmei Hu: Methodology, Investigation. Kelin Li: Visualization. Qing Jia: Methodology. Hai Lin: Resources. Jingpeng Zhao: Resources. Hongchao Jiao: Resources. Xiaojuan Wang: Writing – review & editing, Supervision, Resources, Funding acquisition, Conceptualization. Disclosures The authors have declared no conflicts of interest.